NEW YORK (Reuters) Swiss drugmaker Novartis AG won wider U.S approval for its leukemia drug Tasigna to treat a rare form of the blood cancer at an earlier stage of the disease, the Food and Drug Administration said on Thursday.Tasigna had pre... chronic myeloid leukemia
To comment or read full article login. No account? Register free.